Brief: Medivir's Licensee Tango Therapeutics Discontinues Development Of Its TNG348 Clinical Program
23/05/2024 14:03
May 23 (Reuters) - Medivir AB MEDIVIR.ST :
* MEDIVIR'S LICENSEE, TANGO THERAPEUTICS, HAS DISCONTINUED
DEVELOPMENT OF ITS TNG348 CLINICAL PROGRAM
* TRIAL OF TNG348, A NOVEL USP1 INHIBITOR, IS BEING
TERMINATED DUE
TO TOXICITY OBSERVED IN INITIAL STUDY COHORTS.
* ANNOUNCEMENT BY TANGO THERAPEUTICS HAS NO IMPACT ON
MEDIVIR'S
FOCUS AND DEVELOPMENT EFFORTS
Source text for Eikon: ID:nWkr6FD9C0
Further company coverage: MEDIVIR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))